Hosein Kouros-Mehr, Senior Vice President at Myriad Genetics, shared a post on LinkedIn:
“I’m happy to share that I’m starting a new position as Senior Vice President at Myriad Genetics!
Thirty years after cloning BRCA1, Myriad Genetics is re-emerging as a major innovator in oncology with products spanning the cancer patient journey, from germline and somatic tumor testing to companion diagnostics, prognostic products, and ultra-sensitive MRD testing.
I look forward to partnering with my colleagues in biotech and pharma to improve the success rate of cancer clinical trials and delivering on the promise of personalized medicine. Most of all, I look forward to helping doctors and patients with better tools designed to prevent, diagnose, and manage cancer.
We can’t develop the next wave of cancer medicines without next-generation cancer diagnostics. The journey continues!”